224 related articles for article (PubMed ID: 25387601)
21. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
[TBL] [Abstract][Full Text] [Related]
22. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
23. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV
Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301
[TBL] [Abstract][Full Text] [Related]
25. Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
Modest DP; Brodowicz T; Stintzing S; Jung A; Neumann J; Laubender RP; Ocvirk J; Kurteva G; Papai Z; Knittelfelder R; Kirchner T; Heinemann V; Zielinski CC
Oncology; 2012; 83(5):241-7. PubMed ID: 22948721
[TBL] [Abstract][Full Text] [Related]
26. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
27. A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study.
Matsumura M; Hasegawa K; Oba M; Yamaguchi K; Uetake H; Yoshino T; Morita S; Takahashi K; Unno M; Shimada Y; Muro K; Matsuhashi N; Mori M; Baba H; Shimada M; Mise Y; Kawaguchi Y; Kagimura T; Ishigure K; Saiura A; Sugihara K; Kokudo N
Langenbecks Arch Surg; 2022 Jun; 407(4):1345-1356. PubMed ID: 35211831
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
30. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
31. Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.
Dobi E; Monnien F; Kim S; Ivanaj A; N'Guyen T; Demarchi M; Adotevi O; Thierry-Vuillemin A; Jary M; Kantelip B; Pivot X; Godet Y; Degano SV; Borg C
Clin Colorectal Cancer; 2013 Mar; 12(1):28-36. PubMed ID: 23083634
[TBL] [Abstract][Full Text] [Related]
32. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis.
Petrelli F; Barni S;
Int J Colorectal Dis; 2012 Aug; 27(8):997-1004. PubMed ID: 22358385
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study.
Feng Q; Wei Y; Ren L; Zheng P; Yu Y; Ye Q; Ding J; Chen J; Chang W; Zhong Y; Zhu D; Lin Q; Yang L; Qin X; Xu J
Oncotarget; 2016 Mar; 7(10):11380-96. PubMed ID: 26863631
[TBL] [Abstract][Full Text] [Related]
34. [Effect of KRAS mutation on efficacy of Cetuximab combined with chemotherapy in advanced colorectal cancer patients].
Pu XX; Deng YH; Xu F; Xiao J; Guo HQ; Huang H; Tian Y; He YJ; Lin TY
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Nov; 12(6):594-7. PubMed ID: 19921572
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
36. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
[TBL] [Abstract][Full Text] [Related]
37. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
[TBL] [Abstract][Full Text] [Related]
38. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
[TBL] [Abstract][Full Text] [Related]
39. Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab.
Basso M; Dadduzio V; Ardito F; Lombardi P; Strippoli A; Vellone M; Orlandi A; Rossi S; Cerchiaro E; Cassano A; Giuliante F; Barone C
Medicine (Baltimore); 2016 May; 95(20):e3722. PubMed ID: 27196492
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
Fornaro L; Baldi GG; Masi G; Allegrini G; Loupakis F; Vasile E; Cupini S; Stasi I; Salvatore L; Cremolini C; Vincenzi B; Santini D; Tonini G; Graziano F; Ruzzo A; Canestrari E; Magnani M; Falcone A
Crit Rev Oncol Hematol; 2011 Jun; 78(3):243-51. PubMed ID: 20619672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
